NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
5/8 — Partial
Priority Review
GIAPREZA (angiotensin ii) by Immuno Technologies is 12. First approved in 2017.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIAPREZA (angiotensin II) is a synthetic vasoconstrictor approved in 2017 for intravenous use in critical care settings. It raises blood pressure through direct G-protein-coupled receptor binding on vascular smooth muscle, triggering vasoconstriction and aldosterone release. The drug addresses a narrow but clinically important niche in refractory hypotension management.
Peak10.5 years to LOE
Product is at peak maturity post-launch; team size and investment likely stable, with focus shifting toward retention and expansion rather than aggressive growth.
Mechanism of Action
12.1. Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates…
Pharmacologic Class:
Vasoconstrictor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Started Jan 2026
15 enrolled
Liver Cancer (Locally Advanced or Metastatic)Liver Cancer Adult
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Started Sep 2025
30 enrolled
Vasodilatory Shock
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
Started Nov 2024
30 enrolled
Septic ShockCirrhosisVasodilatory Shock+1 more
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
Started Jul 2024
214 enrolled
Vasodilatory Shock
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Started May 2009
123 enrolled
Heart Failure
Worked on GIAPREZA at Immuno Technologies? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.